Ambient Electric Arc Ionization for Versatile Sample Analysis Using Mass Spectrometry

The Analyst ◽  
2021 ◽  
Author(s):  
Yuanji Gao ◽  
Yuan Li ◽  
Binpeng Zhan ◽  
Quan He ◽  
Heping Zhu ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Electric Arc ◽  
Ion Source ◽  
Sample Analysis ◽  
Ionization Technique ◽  
Soft Ionization

A novel, convenient ambient electric arc ionization (AEAI) device was developed as mass spectrometry ion source for versatile sample analysis. AEAI could be considered as a soft ionization technique in...

A new soft ionization technique for mass spectrometry of complex molecules

1980 ◽  
Vol 102 (18) ◽  
pp. 5931-5933 ◽  
Author(s):  
C. R. Blakley ◽  
J. J. Carmody ◽  
M. L. Vestal
Keyword(s):  
Mass Spectrometry ◽  
Complex Molecules ◽  
Ionization Technique ◽  
Soft Ionization

Reduction Reactions in the Ion Source in Electron Ionization Mass Spectrometry

2020 ◽  
Vol 75 (13) ◽  
pp. 1685-1692
Author(s):  
D. M. Mazur ◽  
M. E. Zimens ◽  
Th. B. Latkin ◽  
N. V. Ul’yanovskii ◽  
V. B. Artaev ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Ion Source ◽  
Electron Ionization ◽  
Electron Ionization Mass Spectrometry ◽  
Ionization Mass Spectrometry ◽  
Ionization Mass ◽  
Reduction Reactions

Thermal bursting ionization for ambient mass spectrometry

RSC Advances ◽  
2016 ◽  
Vol 6 (3) ◽  
pp. 2496-2499 ◽  
Author(s):  
Jiying Pei ◽  
Kefu Yu ◽  
Yinghui Wang
Keyword(s):  
Mass Spectrometry ◽  
Ambient Ionization ◽  
Ambient Mass Spectrometry ◽  
Sample Analysis ◽  
Liquid Sample ◽  
Ionization Source ◽  
Complex Liquid

Ambient ionization source, thermal bursting ionization (TBI), was characterized for complex liquid sample analysis with mass spectrometry.

scholarly journals Method comparison of HPLC-ninhydrin-photometry and UHPLC-PITC-tandem mass spectrometry for serum amino acid analyses in patients with complex congenital heart disease and controls

Metabolomics ◽  
2020 ◽  
Vol 16 (12) ◽  
Author(s):  
Miriam Michel ◽  
Christina Salvador ◽  
Verena Wiedemair ◽  
Mark Gordian Adam ◽  
Kai Thorsten Laser ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Congenital Heart Disease ◽  
High Performance Liquid Chromatography ◽  
Heart Disease ◽  
Liquid Chromatography ◽  
Tandem Mass Spectrometry ◽  
High Performance ◽  
Congenital Heart ◽  
Tandem Mass ◽  
Sample Analysis

Abstract Introduction Metabolomics studies are not routine when quantifying amino acids (AA) in congenital heart disease (CHD). Objectives Comparative analysis of 24 AA in serum by traditional high-performance liquid chromatography (HPLC) based on ion exchange and ninhydrin derivatisation followed by photometry (PM) with ultra-high-performance liquid chromatography and phenylisothiocyanate derivatisation followed by tandem mass spectrometry (TMS); interpretation of findings in CHD patients and controls. Methods PM: Sample analysis as above (total run time, ~ 119 min). TMS: Sample analysis by AbsoluteIDQ® p180 kit assay (BIOCRATES Life Sciences AG, Innsbruck, Austria), which employs PITC derivatisation; separation of analytes on a Waters Acquity UHPLC BEH18 C18 reversed-phase column, using water and acetonitrile with 0.1% formic acid as the mobile phases; and quantification on a Triple-Stage Quadrupole tandem mass spectrometer (Thermo Fisher Scientific, Waltham, MA) with electrospray ionisation in the presence of internal standards (total run time, ~ 8 min). Calculation of coefficients of variation (CV) (for precision), intra- and interday accuracies, limits of detection (LOD), limits of quantification (LOQ), and mean concentrations. Results Both methods yielded acceptable results with regard to precision (CV < 10% PM, < 20% TMS), accuracies (< 10% PM, < 34% TMS), LOD, and LOQ. For both Fontan patients and controls AA concentrations differed significantly between methods, but patterns yielded overall were parallel. Conclusion Serum AA concentrations differ with analytical methods but both methods are suitable for AA pattern recognition. TMS is a time-saving alternative to traditional PM under physiological conditions as well as in patients with CHD. Trial registration number ClinicalTrials.gov Identifier NCT03886935, date of registration March 27th, 2019 (retrospectively registered).

Sign in / Sign up

Export Citation Format

Share Document